Bourne Lent Asset Management Inc Amgen Inc Transaction History

Bourne Lent Asset Management Inc

$261 Million
Q2 2024

A detailed history of Bourne Lent Asset Management Inc transactions in Amgen Inc stock. As of the latest transaction made, Bourne Lent Asset Management Inc holds 9,745 shares of AMGN stock, worth $3.14 Million. This represents 1.17% of its overall portfolio holdings.

Number of Shares

9,745

Previous 9,820 0.76%

Holding current value

$3.14 Million

Previous $2.79 Million 9.03%

% of portfolio

1.17%

Previous 1.13%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$262.75 - $319.31 $19,706 - $23,948	-75 Reduced 0.76%	9,745 $3.04 Million
Q1 2024 Apr 12, 2024	BUY	$268.87 - $324.56 $26,887 - $32,456	100 Added 1.03%	9,820 $2.79 Million
Q4 2023 Jan 19, 2024	BUY	$255.7 - $288.46 $86,938 - $98,076	340 Added 3.62%	9,720 $2.8 Million
Q2 2023 Jul 17, 2023	SELL	$214.27 - $253.37 $74,994 - $88,679	-350 Reduced 3.6%	9,380 $2.08 Million
Q4 2022 Jan 23, 2023	SELL	$229.03 - $291.01 $62,296 - $79,154	-272 Reduced 2.72%	9,730 $0
Q1 2022 Apr 26, 2022	BUY	$219.27 - $242.57 $87,708 - $97,028	400 Added 4.17%	10,002 $2.42 Million
Q4 2021 Jan 20, 2022	BUY	$198.88 - $227.6 $887,999 - $1.02 Million	4,465 Added 86.92%	9,602 $2.16 Million
Q4 2020 Jan 27, 2021	SELL	$216.38 - $257.67 $43,276 - $51,534	-200 Reduced 3.75%	5,137 $1.18 Million
Q1 2020 Apr 17, 2020	BUY	$182.24 - $241.7 $27,336 - $36,255	150 Added 2.89%	5,337 $1.08 Million
Q4 2019 Jan 24, 2020	BUY	$189.21 - $243.2 $56,763 - $72,960	300 Added 6.14%	5,187 $1.25 Million
Q1 2018 Apr 20, 2018	SELL	$169.43 - $198.0 $74,549 - $87,120	-440 Reduced 8.26%	4,887 $833,000
Q3 2017 Oct 16, 2017	BUY	$167.29 - $191.0 $891,153 - $1.02 Million	5,327	5,327 $993,000

Others Institutions Holding AMGN

# of Institutions

3,054

Shares Held

409M

Call Options Held

7.19M

Put Options Held

6.26M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $173B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bourne Lent Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bourne Lent Asset Management Inc with notifications on news.

Account

Bourne Lent Asset Management Inc Amgen Inc Transaction History